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Antineoplastic drugs are a heterogeneous group of chemicals used in the treatment of cancer, 
and have been proved by IARC to be mutagens, carcinogens and teratogens agents (Fucic et 
al., 1998; Burgaz et al., 1999; Sessink & Bos, 1999; Bouraoui et al., 2011; Gulten et al., 2011; 
Buschini et al., 2013). In general, chemicals that interact directly with DNA by biding covalently 
or by intercalating, or indirectly by interfering with DNA synthesis, were among the first 
chemotherapeutics developed (Jackson et al., 1996). Also, these drugs can induce reactive 
oxygen species that can lead to DNA damage and, consequently, mutations (Rombaldi et al., 
2008). These drugs are often used in combination to achieve synergistic effects on tumour 
cells resulting from their differing modes of action. However, most if not all of these chemical 
agents are generally nonselective and, along with tumour cells, normal cells may undergo 
cytotoxic/genotoxic damage (Connor, 2006; Kopjar et al., 2006; Villarini et al., 2012). The in 
vivo exposure to antineoplastic drugs has been shown to induce different types of lesions in 
DNA, depending on the particular stage of cell cycle at the time of treatment. Besides the 
patients that use these drugs as a treatment, workers that handle and/or administer these 
drugs can be exposed to these substances; namely pharmacy, and nursing personnel in 
hospital context. The comet assay identifies injuries which are still reparable, such as single 
and double-strand DNA breaks, alkali labile lesions that are converted to strand breaks under 
alkaline conditions and single-strand breaks associated with incomplete excision repair sites 
(Villarini et al., 2012), thus providing information about recent exposures (Laffon et al., 2005). 
In particular, the comet assay with the use of enzymes, which recognizes and cuts specifically 
oxidized DNA bases allows for the evaluation of oxidative DNA damage (Collins, 1999). It is one 
of the most used methods in biomonitoring studies of genotoxicity on blood lymphocytes 
(Cavallo et al., 2009), and is widely used to evaluate the genotoxic effects of exposure to 
specific antineoplastic drugs in several in vitro and in vivo studies (Digue et al., 1999; Blasiak et 
al., 2000; Brahnam et al., 2004). DNA glycosylase (OGG1) represents the main mechanism of 
protecting the integrity of the human DNA with respect to 8-OHdG (Hu & Ahrendt, 2005; Jiao 
et al., 2007), the most well studied biomarker of oxidative damage. Some findings indicate that 
the inactivation of OGG1 plays a role in the multistage process of carcinogenesis. The human 
OGG1 gene is located on chromosome 3 (3p26), and encodes a bifunctional DNA glycolylase 
endowed with an AP lyase activity. This is a region frequently lost in various types of cancer, 
especially in small-cell lung cancers where loss of heterozygosity in nearly 100% of the cases 
can be observed. Loss of one OGG1 allele may lead to a moderate generation of 8-OHdG in 
DNA. However, loss of both alleles would abrogate OGG1 activity imposing an increased risk of 
mutagenicity on the cell due to the imbalance of oxidative burden and accumulation of 8-
OHdG in DNA (Pilger & Rüdiger, 2006). The product of OGG1 gene exhibits specificity and 
activity for the excision of 8-OHdG (Boiteux & Radicella, 1999; Cooke et al., 2003; Au et al., 
2004), and has a major role in the prevention of ROS-induced carcinogenesis (Cooke et al., 
2003). A common polymorphism is Ser326Cys, which affects over 50% of Chinese and 
Japanese and approximately 33-41% of Caucasian population (Hu & Ahrendt, 2005). The OGG1 
has a C→G polymorphism at position 1245 in exon 7 which causes the substitution of serine by 
cysteine at codon 326 (Kohno et al., 1998) and it is associated with increased risk for cancer 
(Macpherson et al., 2005). The study population consisted of 46 exposed subjects working as 
pharmacists, pharmacy technicians, and nurses that handle antineoplastic drugs of two 
hospital units, and 46 unexposed control subjects. Isolated lymphocytes were cryopreserved 
following the protocols of Duthie et al. (2002) and Singh & Lai, (2009). Briefly, isolated 
lymphocytes suspended in RPMI medium with L-glutamine were either centrifuged (600g, 10 
min) and ressuspended in freezing mix (90% v/v heat-inactivated fetal calf serum and 10% v/v 
DMSO), frozen at -1C/min in polystyrene and stored at -80C. For analysis of DNA damage and 
oxidative damage a modification of the comet assay (originally described by (Singh et al., 1988) 
was used to measure the basal level of DNA oxidation in lymphocytes (Collins, 2009). We 
measured also DNA oxidative damage by using FPG [kindly donated by Prof. Andrew Collins 
(Department of Nutrition, University of Oslo, Norway)]. The slides were dried at room 
temperature, stained with 25 µl DAPI (1 µg/mL) and visualized. Percentage of DNA in the tail 
and oxidative damage parameters were measured using Zeiss AxioScope.A1 fluorescence 
microscope and Comet Assay IV capture system (Perceptive Instruments ® software) and 50 
nucleoids were scored per gel. The genotype of the polymorphisms OGG1 (rs1052133) was 
studied by Real Time PC R using the iCycler iQ®Multicolor Real-Time PCR. It was found higher 
mean levels of % DNA in tail and DNA oxidative damage in the exposed group (15.18±1.40 and 
5.32±0.54, respectively) in comparison with controls (12.42±1.24 and 4.59±0.59, respectively). 
However, no statiscally significant differences (Mann-Whitney test, p>0.05) were found 
between subjects with and without exposure. No significant differences were observed in 
genotypic and allelic frequencies in OGG1 polymorphisms under study between exposed and 
controls (Fisher’s exact test, p>0.05) and no consistent trend regarding the variation of 
biomarkers measured with alkaline comet assay and OGG1 polymorphisms was found 
(Kruskal-Wallis test, p>0.05). Our results suggest that occupational exposure to antineoplastic 
drugs in healthcare workers induces DNA damage but the increase compared to controls was 
not significant, being in line with studies from Ursini et al., (2006) and Buchini et al. (2013). A 
possible explanation may have to do with comet assay predominantly detecting single-strand 
breaks and alkali-labile sites, which are induced by antineoplastic drugs (Kopjar et al., 2009). 
Since both types of DNA damage are continuously and efficiently repaired, the measured 
damage level is a result of equilibrium between the amount of DNA damage inflicted and the 
speed of repair (Kopjar & Garaj-Vrhovac, 2001). An important aspect to consider is the fact of 
antineoplastic drugs are well-known cross-linking agents, which can increase the effective 
molecular weight of DNA, are thereby are known to reduce the ability of DNA containing 
strand breaks to migrate in an electric field (Villarini et al., 2011). Occupational exposure to 
antineoplastic drugs is associated with genotoxic effects, although comet assay analyzed 
parameters were higher in exposed comparing with controls, were not significant. Also the 
study of the susceptibility biomarkers did not show statistical significant differences, the small 
size of our sample hampered the finding of a possible association, let alone a causality 
relationship.  
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